Lindbrook Capital, LLC Bluebird Bio, Inc. Transaction History

Lindbrook Capital, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	BUY	$1.32 - $4.83 $641 - $2,347	486 Added 298.16%	649 $0
Q3 2023 Oct 25, 2023	SELL	$3.02 - $4.05 $395 - $530	-131 Reduced 44.56%	163 $0
Q2 2023 Jul 28, 2023	BUY	$2.79 - $5.03 $599 - $1,081	215 Added 272.15%	294 $0
Q1 2023 Apr 26, 2023	SELL	$3.14 - $8.22 $2,320 - $6,074	-739 Reduced 90.34%	79 $0
Q4 2022 Jan 24, 2023	BUY	$5.77 - $8.49 $2,942 - $4,329	510 Added 165.58%	818 $0
Q3 2022 Nov 10, 2022	BUY	$3.75 - $7.39 $971 - $1,914	259 Added 528.57%	308 $2,000
Q2 2022 Aug 01, 2022	SELL	$2.94 - $5.23 $473 - $842	-161 Reduced 76.67%	49 $0
Q1 2022 Apr 21, 2022	BUY	$4.07 - $10.6 $313 - $816	77 Added 57.89%	210 $1,000
Q3 2021 Nov 05, 2021	BUY	$11.24 - $21.0 $1,494 - $2,793	133 New	133 $3,000
Q2 2021 Jul 27, 2021	SELL	$18.04 - $22.09 $974 - $1,192	-54 Closed	0 $0
Q1 2021 Apr 28, 2021	SELL	$16.59 - $33.89 $613 - $1,253	-37 Reduced 40.66%	54 $2,000
Q4 2020 Jan 27, 2021	BUY	$27.5 - $37.92 $2,502 - $3,450	91 New	91 $4,000
Q3 2020 Nov 03, 2020	SELL	$34.44 - $43.75 $551 - $700	-16 Closed	0 $0
Q2 2020 Jul 27, 2020	BUY	$27.12 - $45.97 $433 - $735	16 New	16 $1,000
Q1 2020 Apr 22, 2020	BUY	$26.16 - $63.5 $0 - $0	0 New	0 $0

20.3M

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $315M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.